Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance with Second Cycle

BEVERLY, MA–(Marketwire – April 21, 2010) –  Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that it presented a poster session today at the American Association for Cancer Research (AACR) 101st Annual Meeting in Washington, D.C. This poster session included data on Kevetrin that have not previously been made public. These data showed that the efficacy of Kevetrin in a mouse model of drug resistant lung cancer increases with increasing dose. These data also show that the administration of a second cycle of therapy with Kevetrin in the same animal model continues to delay tumor growth without the development of resistance. In addition to the new lung cancer data, the poster includes data showing a positive effect for Kevetrin in animal models of drug-resistant colon and breast cancer cell lines. The poster, titled “Novel Small Molecule has Potent Anti-tumor Activity in Drug Resistant Human Carcinoma Xenograft Models,” is available on the Cellceutix web site at www.cellceutix.com.

“These data are another important piece of the Kevetrin story,” said its Chief Scientific Officer, Dr. Krishna Menon. ”The continued and undiminished anti-tumor effect when a second cycle is administered is particularly significant, showing that resistance to Kevetrin is not developing.”

The experiment consisted of five groups of animals: controls, Kevetrin 50 mg/kg, Kevetrin 100 mg/kg and Kevetrin 200 mg/kg. In the 50 mg/kg, 100 mg/kg, and 200 mg/kg groups, Kevetrin was administered in three doses every other day. In an additional group, 200 mg/kg Kevetrin was administered in three doses every other day followed by a second cycle administered 10 days after the first cycle. The 100 mg/kg and 200 mg/kg Kevetrin groups (one or two cycles) showed significant delays in tumor growth compared to controls. In addition, tumor growth delay with Kevetrin was dose dependent. No resistance was observed with the second cycle of Kevetrin.

“We are extremely pleased to be able to present these important new data at AACR,” said George Evans, CEO of Cellceutix. ”These data again show strong activity in a resistant lung cancer cell line and the fact that Kevetrin delays tumor growth in a dose dependent manner is important as we move toward a phase 1 human trial.”

More information about Kevetrin and the rest of the Cellceutix portfolio is available on the Cellceutix web site at www.cellceutix.com.